EGFR and non-small cell lung carcinoma: In a double-blind, phase III trial (FLAURA), osimertinib showed efficacy superior to that of first-generation gefitinib or erlotinib in the first-line treatment of EGFR mutation (DEL or L858R)-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events [8, 9].